Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol., 14 October 2022
Sec. Respiratory Pharmacology
This article is part of the Research Topic Pulmonary Fibrosis: one manifestation, various diseases View all 12 articles

World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease

Lesley Ann Saketkoo,,,
Lesley Ann Saketkoo1,2,3,4*Reuben Escorpizo,Reuben Escorpizo5,6Janos VargaJanos Varga7Kevin John Keen,Kevin John Keen8,9Kim Fligelstone,Kim Fligelstone10,11Surinder S. BirringSurinder S. Birring12Helene Alexanderson,Helene Alexanderson13,14Henrik Pettersson,Henrik Pettersson13,14Humza Ahmad Chaudhry,,Humza Ahmad Chaudhry1,2,3Janet L. PooleJanet L. Poole15Malin Regardt,Malin Regardt13,14Daphne LeSageDaphne LeSage16Catherine SarverCatherine Sarver17Joseph LanarioJoseph Lanario18Elisabetta RenzoniElisabetta Renzoni19Mary Beth ScholandMary Beth Scholand20Matthew R. Lammi,,Matthew R. Lammi1,2,4Otylia Kowal-BieleckaOtylia Kowal-Bielecka21Oliver DistlerOliver Distler22Tracy Frech,Tracy Frech23,24Lee Shapiro,Lee Shapiro25,26Cecilia VarjuCecilia Varju27Elizabeth R. VolkmannElizabeth R. Volkmann28Elana J. BernsteinElana J. Bernstein29Marjolein Drent,Marjolein Drent30,31Ogugua Ndili ObiOgugua Ndili Obi32Karen C. Patterson,Anne-Marie Russell,
Karen C. Patterson33,34www.frontiersin.orgAnne-Marie Russell35,36*The Global Fellowship on Rehabilitation The Global Fellowship on RehabilitationExercise in Systemic Sclerosis (G-FoRSS) Exercise in Systemic Sclerosis (G-FoRSS)
  • 1New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, United States
  • 2University Medical Center—Comprehensive Pulmonary Hypertension Center & Interstitial Lung Disease Clinic Programs, New Orleans, LA, United States
  • 3Tulane University School of Medicine, New Orleans, LA, United States
  • 4Louisiana State University Health Sciences Center, Division of Pulmonary Medicine—New Orleans, New Orleans, LA, United States
  • 5Department of Rehabilitation and Movement Science, The University of Vermont, Burlington, VT, United States
  • 6Swiss Paraplegic Research, Nottwil, Switzerland
  • 7Department of Pulmonology, Semmelweis University, Budapest, Hungary
  • 8Department of Mathematics and Statistics and Health Research Institute, University of Northern British Columbia, Prince George, BC, Canada
  • 9Department of Medicine, University of British Columbia & Centre for Heart Lung Innovation, Providence Research, Vancouver, BC, Canada
  • 10Patient Research Partner Scleroderma & Raynaud Society, UK (SRUK) and Federation of European Scleroderma Associations, London, United Kingdom
  • 11Royal Free Hospital Scleroderma Unit, London, United Kingdom
  • 12Division of Asthma, Allergy and Lung Biology, King’s College London, London, United Kingdom
  • 13Women’s Health and Allied Health Professionals, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden
  • 14Department of Medicin, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden
  • 15Occupational Therapy Graduate Program, University of New Mexico, Albuquerque, NM, United States
  • 16Patient Research Partner, New Orleans, LA, United States
  • 17Patient Research Partner, Baltimore, MD, United States
  • 18Research Fellow in Respiratory Health—Exeter Respiratory Institute Royal Devon University Hospitals NHS Foundation Trust, Exeter, United Kingdom
  • 19Royal Brompton Hospital, National Heart and Lung Institute, London, United Kingdom
  • 20Pulmonary Medicine, University of Utah, Salt Lake City, UT, United States
  • 21University of Bialystok, Bialystok, Poland
  • 22Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland
  • 23Division of Rheumatology Vanderbilt University School of Medicine, Nashville, TN, United States
  • 24Pulmonary Medicine, University of Utah, Salt Lake City, UT, United States
  • 25Division of Rheumatology, Albany Medical Center, Albany, NY, United States
  • 26Steffens Scleroderma Foundation, Albany, NY, United States
  • 27Department of Rheumatology and Immunology, Medical School, University of Pécs, Pecs, Hungary
  • 28Department of Medicine, David Geffen School of Medicine, UCLA Scleroderma Program and UCLA CTD-ILD Program, Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, United States
  • 29Department of Medicine, Columbia University/New York-Presbyterian Scleroderma Program, Division of Rheumatology, Columbia University College of Physician2s and Surgeons, New York, NY, United States
  • 30Department of Pulmonology, Interstitial Lung Diseases (ILD) Center of Excellence, St. Antonius Hospital, Nieuwegein, Netherlands
  • 31Department of Pharmacology and Toxicology, Faculty of Health and Life Sciences, Maastricht University, Nieuwegein, Netherlands
  • 32Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, United States
  • 33Department of Clinical & Experimental Medicine, Brighton & Sussex Medical School, Falmer, United Kingdom
  • 34Division Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
  • 35Respiratory Institute to Exeter Respiratory Innovation Center, University of Exeter, Exeter, United Kingdom
  • 36Respiratory Medicine, Royal Devon University Healthcare NHS Foundation Trust, London, United Kingdom

Background: The World Health Organization (WHO) introduced the International Classification of Functioning, Disability, and Health (ICF) as a scientific method of disability data collection comprised of >1,200 categories describing the spectrum of impairment types (functional, symptoms-based and anatomical) under the bio-psycho-social model with consideration of environmental and personal factors (pf). ICF Core Sets and ICF Checklists are streamlined disease-specific resources for clinical use, service provision, and for use in health economics and health policy. ICF can disclose strengths and weaknesses across multiple patient-reported outcome measures (PROMs) and help consolidate best-fitting question-items from multiple PROMs. Interstitial lung diseases (ILDs), are generally progressive, with restrictive physiology sometimes occurring in the context of multi-organ autoimmunity/inflammatory conditions such as connective tissue diseases (CTDs). In spite of significant associated morbidity and potential disability, ILD has yet to be linked to the ICF.

Methods: Each instrument and their question-items within the consensus-recommended core sets for clinical trials in ILD were deconstructed to single concept units, and then linked per updated ICF linkage rules. Inter-linker agreement was established. Three additional subsequently validated measures were also included.

Results: One-hundred-eleven ICF categories were identified for ten PROMs and three traditional objective measures that were amenable to ICF linkage. The proportion of agreement ranged from 0.79 (95% CI: 0.62, 0.91) to 0.93 (0.76, 0.99) with the overall proportion of inter-linker agreement being very high 0.86 (0.82, 0.89) for the initial instruments, with 94–100% for the three additional PROMs. Thirty-four new ‘Personal Factors’ emerged to capture disease-specific qualities not elsewhere described in ICF, e.g. ‘pf_embarrassed by cough’ or ‘pf_panic/afraid when can’t get a breath’.

Conclusion: This first known effort in ICF linkage of ILD has provided important revelations on the current utility of the ICF in lung disease. Results have indicated areas for meaningful assessment of ICF descriptors for lung impairment. The mapping across PROMs provides insight into possibilities of developing more streamline and precise instrumentation. Finally, familiarity with the ICF in ILD may enable clinicians to experience a smoother transition with the imminent harmonization of ICD and ICF, ICD-11.

Introduction

Interstitial lung diseases (ILD) are a heterogeneous group of predominately restrictive lung diseases imparting significant morbidity and mortality (Travis et al., 2013; Wijsenbeek and Cottin, 2020). Idiopathic pulmonary fibrosis (IPF) is a progressive pauci-immune fibrotic process predominantly involving the lungs and with no known cure (Spagnolo et al., 2018). Connective tissue diseases (CTD) such as systemic sclerosis, inflammatory myopathy, Sjogren’s syndrome and rheumatoid arthritis (RA) affect the lungs in the setting of other systemic/multi-organ autoimmunity with radiographic and pathological patterns varying in degrees of inflammatory and/or fibrotic progression (Wijsenbeek and Cottin, 2020; Ruaro et al., 2021). Through iterative medical expert and patient consensus methodology (Saketkoo et al., 2014a; Saketkoo et al., 2014b), recent efforts identified a minimum set of instruments for inclusion in clinical trials and longitudinal observational studies in IPF and CTD-ILD, respectively.

The World Health Organization’s (WHO) International Classification of Functioning, Disability and Health (ICF) is an alphanumeric classification system integrating the bio-psychosocial model of health and was officially adopted by the World Health Assembly in 2001 (Figure 1 and online supplement.).

FIGURE 1
www.frontiersin.org

FIGURE 1. Interactions between domains of ICF in relation to the health condition. Courtesy of LA Saketkoo, with permission, rights reserved.

As with the WHO’s other classification system, the International Classification of Diseases (ICD), a system originally developed to quantify burden of specific health conditions (diagnoses), the ICF can be used on global, national, regional, local, and institutional levels. The ICF was originally devised as a standardized means to scientifically assess the global burden of disability and chronic disease (World Health Organization, 2001; World Health Organization Website, 2015), thus providing guidance for reimbursement, infrastructural support, allotment of research and service funding, and, importantly, policymaking. Through a hierarchical mechanism of over 1,200 “categories” (or codes) that depict functioning and disability (World Health Organization International Classification of Functioning Disability and Health, 2001), the ICF attempts to describe the spectrum of impairment type (symptomatic and anatomical) and to quantify the burden of disability of a population, as well as capturing “environmental factors” that either improve function and mitigate disability (such as ramps, assistive technology, medications, supportive family, etc), or that worsen impairment (staired entries, lack of accessible transport, unaffordable assistive aids, etc.).

Beyond epidemiologic and health economics use, the ICF has emerged to be highly versatile and multi-purpose in its utility including clinical assessment of specified health conditions, It initially focused on rehabilitative care (e.g. traumatic brain injury, stroke etc.) and subsequently expanded to other chronic health conditions (e.g. RA, diabetes, or obesity). Clinical applications of the ICF gave rise to the development of ICF Core Sets (collections of ICF categories relevant to a disease) along with ICF Checklists (clinical forms with selected categories from the ICF Core Set), abbreviated collections of ICF categories/codes for specific health conditions that facilitate assessment of symptom burden, impairment, treatment response, side effects and service needs.

ICF Core Sets and Checklists can be administered online or on paper, and are patient or clinician reported. ICF is multi-purpose and can be used along with the Patient Specific Functional Scale St (PSFS) (Stratford et al., 1995; Fairbairn et al., 2012; Patient specific functional scale, 2021), MACTAR (Alemo Munters et al., 2014) or Canadian Occupational Performance Measure (COPM) (Stamm et al., 2004) to help identify and prioritize unique preferences in functional achievements. Similarly, ICF can help disclose strengths and weaknesses across multiple patient-reported outcome measures (PROMs) and consolidate best-fitting question items.

The ICD and ICF classification systems complement each other, and the current WHO intention is to harmonize these two classification systems for ICD-11 (Escorpizo et al., 2013). The Center for Medicare and Medicaid Services (CMS) in the United States (Iezzoni and Greenberg, 2003; Health and Human Services/Centers for Medicare and Medicaid Services, 2000; SocialSecurity Administration, 2013; Escorpizo and Stucki, 2013) has adopted the 11th revision of the ICD, which will integrate the ICD-10 and ICF classifications by simultaneously conveying the diagnosis with the type and degree of impairment (Kohler et al., 2012; Escorpizo et al., 2013; Selb et al., 2015a; Selb et al., 2015b). Our goal in linking ILD to the ICF is the development of disease-specific ICF Core Sets to aid pulmonary-focused clinicians in this transition (Saketkoo et al., 2012a; Selb et al., 2015a). The results provide significant utility beyond our original goals, including ICF language enhancements and mapped variations of current PROMs that may inform improved patient-reported instrumentation.

Methods

The goals of the study are to produce a feasible approach to ICF for clinicians and researchers working in interstitial lung disease, and to foster confidence and familiarity with the ICF during the ICD-11 transition (Escorpizo et al., 2013). Additionally, the study interrogates for needed modifications and updates to advance the current ICF content in pulmonary disease.

Structure of the ICF classification

The ICF Classification consists of two over-arching parts with independent components:

1. Functioning and Disability, the predominant operational part of the classification consists of:

a) “Body Structure” (“s” terms) are abnormalities of anatomical structure, such as that of lung parenchyma (s4301)

b) “Body Function” (“b” terms) are physiologic functions including symptomatic experience of physical, mental and emotional functions e.g. energy/fatigue (b1300), dyspnea (b460), cough (b450) or chest pain (b28011)

c) “Activities and Participation” (“d” terms) are defined under “activities” e.g. lifting (d4300), bathing (d510), cooking (d630), or moving between locations (d460); and under “participation” such as life situations with work (d850) or family (d760).

2. Contextual Factors are divided into:

a) external or “Environmental Factors” (“e” terms) that either positively (e.g., personal assistive devices, e1151) or negatively (e.g., inaccessible transportation, e120) impact functioning

b) internal or “Personal Factors”, a developing ICF area, are individualized factors that potentially influence disability e.g., gender, age, coping styles, behavior and psychological characteristics.

Categories are tiered into “levels” of specificity (e.g., b5 digestive system, b510 ingestion, b5105 swallowing, b51052 esophageal swallowing).

Linking the CTD-ILD and IPF consensus instruments to the ICF

A diverse expert team of clinicians, patients and researchers provided responsive feedback regarding instrument selection, analysis and interpretation. These consensus measures included seven vetted PROMS and four “objective” measures considered for use in clinical trials for IPF and for CTD-ILD (Saketkoo et al., 2014b) (Table 1) as well as three other subsequently validated PROMs (Patel et al., 2012; Russell et al., 2017; Russell, 2018; Swigris et al., 2020) that were included because of anticipated high utilization. Each of these measures was attempted to be linked to ICF categories (Table 2) by two independent investigators (RE,LAS) according to updated ICF linking rules (Cieza et al., 2005). (As the Short Form Health Survey (SF-36) was previously linked by ICF scholars, these linkages were used.) To accomplish the linking, each of the measures were deconstructed to its most basic single-concept units, which required PROM question-items to each be deconstructed. For example, an item querying “mowing lawn makes me breathless” is comprised of two discrete concepts linked individually to ICF, “mowing lawn” and “breathless”. Each concept-item, however, may evoke more than one linkage, such as “mowing lawn” suggests “pushing an object” and “caring for home”. If any item analysis identified discordance, these were resolved between the linkers. This was done by each linker stating their position of support for the items they had chosen, then each stating if they had any positions of disagreement for the discordant items chosen by the other. This was then followed by discussion of each item to keep or dismiss. Irresolvable disagreement between linkers on an item would be decided by at least one person also trained in the ICF (AMR,HA,HP,OD).

TABLE 1
www.frontiersin.org

TABLE 1. Consensus on minimal core sets of instruments and measures for IPF and CTD-ILD trials (Saketkoo et al., 2014b)

TABLE 2
www.frontiersin.org

TABLE 2. Distribution of ICF categories and instrument occurrence per domain with example linkages. (Courtesy of LA Saketkoo, with permission, rights reserved)

Pre-resolution inter-linker agreement was analyzed (KJK) for each instrument with the estimates of the proportion of agreement and confidence intervals according to the exact binomial test using release 3.1.0 of the R statistical software package (Core Team, 2014).

Results

One-hundred and eleven ICF categories were identified under the four ICF components (“Body Structure”, “Body Function”, “Activities and Participation”, and “Environmental Factors”) for nine patient-reported questionnaires and three traditional objective measures (Table 2).

Linking agreement

Agreement between linkers was high (Table 3). The pre-resolution proportion of agreement ranged from 0.79 (95% CI: 0.62, 0.91) to 0.93 (0.76, 0.99) for the five-remaining consensus PROMs (Saketkoo et al., 2014b) (as no linking occurred for Visual Analogue Scale-Patient Global Assessment of Disease Activity (VAS-PtGA) and SF-36) with the overall proportion of inter-linker agreement 0.86 (0.82, 0.89). There was 100% agreement between the linkers for pulmonary function measures of forced vital capacity (FVC) and diffusion capacity (DLCO), and the Overall Extent of ILD on HRCT. There was 94–100% linking agreement for the three additional PROMs (PF/IPF-PROM, King’s Brief Interstitial Lung Disease Questionnaire (K-BILD), and Living with IPF (LIPF) Questionnaire). Initial linking discrepancies were resolved to 100% between linkers without need for arbitration.

TABLE 3
www.frontiersin.org

TABLE 3. Instruments from the previously published CTD-ILD and IPF minimum core sets for clinical trials with instrument comparison and inter-reviewer agreement. (Courtesy of LA Saketkoo, with permission, rights reserved)

Linkages

Of the combined total 111 linkages identified, 28 fell under “Body Function”, one under “Body Structure” (lung), 71 under “Activities and Participation” and 11 under “Environmental Factors”. All-Cause Mortality and the VAS-PtGA were not definable in ICF terms. Extent of ILD on HRCT was the only measure demonstrating linkage under “Body Structure” representing a single category, s4301, “Structure of Lungs”.

The ICF contained no direct and specific linkages for the pervasive ILD symptoms of breathlessness and cough. To address this, many new linkages created to temporarily accommodate the concepts held in the PROMs. However, we propose these enduring ICF additions:

• two new ICF categories under “additional respiratory functions”: “cough(b4501) and “phlegm production(b4502),

• one new ICF category under “respiratory functions”: “respiratory flow including airflow interrupted by inspiratory cough”(b4403), and

• three under “sensations associated with cardiovascular and respiratory functions”: “sensation of breathlessness(b4600),sensation of air hunger(b4601),wheezing(b4602).

Regarding concepts of high ILD relevance (Swigris et al., 2005; Saketkoo et al., 2014a; Saketkoo et al., 2014b) cited by people living with ILD, there appeared to variation of frequency across PROMs.

Exercise tolerance (b455), as did respiratory symptoms (b440-b460) demonstrated linkage in all PROMS except SF-36. Depth of respiration (b4402) was queried in two PROMs, the Dyspnea-12 (D-12) and LIPF.Coughing” in any form was noted in only three PROMs: LCQ, SGRQ, and LIPF. “Cough with deep inspiration” and “coughing with over-exertion” were queried in LIPF and “bouts of coughing” in LCQ. Linkages relating to voice quality (b3101), speaking (d330) and conversation (d350,d3600) were represented by the LCQ and LIPF.

Of nine PROMs, Energy level, (b1300) and fatiguability (b4552) was queried in six of the nine included PROMs (D-12, LCQ, SF-36, SGRQ, PF/IPF-PROM, LIPF). While sleep (b134) was queried in three PROMs (LCQ, SGRQ, LIPF). Ability to “carry out daily routine” (d230) demonstrated linkage in five PROMs (LCQ, SF-36, PF/IPF-PROM, K-BILD, LIPF); but only the LIPF queried complexity of task performance and did so in multiple dimensions (d210, d2100, d2102, d220, d2202) as well as self-pacing (d2309_pace self). While the University of California San Diego-Shortness of Breath Questionnaire (UCSD-SBQ), accounted for unique linkages (Table 4, 5) all of which occurred under “Activities and Participation” and related to ability to sit, stand, to perform domestic care and move around outside the house; while both the UCSD-SBQ and the LIPF demonstrated linking to more highly detailed levels of self-care activities such dental care, washing and grooming.

TABLE 4
www.frontiersin.org

TABLE 4. Categories according to instrument (Courtesy of LA Saketkoo, with permission, rights reserved)

TABLE 5
www.frontiersin.org

TABLE 5. Categorical concepts unique to a single instrument (Courtesy LA Saketkoo, with permission, rights reserved.)

The UCSD-SBQ is the only included PROM to query self-nourishment (d550) and sexual activity (d7702). Concepts of financial solvency, such as maintaining remunerative employment and assets were only queried in the K-BILD and LCQ.

Personal and environmental factors

Thirty-four “Personal Factors” (Table 6) reflected disease-specific qualities not described elsewhere in the ICF, e.g. “pf_embarrassed by cough” or “pf_panic/afraid when can’t get a breath”. “Personal Factors” mainly captured the emotional impact of living with ILD ranging from episodic feelings such as panic, fright, distress, frustration and embarrassment; to those of more goading nature such as fear, worry, agitation; and more chronic undercurrents of emotion such as anxiety, coping with uncertainty, fear of symptoms and thinking about death. “Personal Factors” also described perceptions of health status such as quality of life and frailty, “Environmental Factors” related to the attitudes of others (family e410/e415, friends e420, acquaintances e425, societal e460) potentially impacting impairment were predominantly represented by the LCQ and SGRQ. SGRQ uniquely queried terrain (e2100) and circadian timing of symptoms (e2450). LCQ, K-BILD uniquely queried air quality (e260) and assets (e1650, e1651), respectively. LIPF uniquely queried about products/technology for personal use (e111_supplemental oxygen) and personal care providers (e340).

TABLE 6
www.frontiersin.org

TABLE 6. Additional considerations for ICF ILD linkages from instruments and domains (Courtesy LA Saketkoo, with permission, rights reserved)

Discussion

Herein, we provide a reference of 111 ICF categories describing impairment in ILD for use in the clinical setting with potential transferability for clinical trial use, especially with regard to optimization of PROMs. The importance of ICF Core Sets is heightened in rare or commonly misunderstood diseases and their manifestations, as they are intended to provide an assembly of biophysical and psychosocial features relevant and important to a health condition. In so doing, they can provide a clinical focus for patient experiences of disease that may often go under-recognized; and can potentially be teaching tools to familiarize clinicians with the patient experience of rarer diseases.

Disability is the impact of a health condition on a person’s global functioning characterized by body-level impairments, society-level participation limitations and impact on psychological well-being. “Activities and Participation”, representing >70% of the linkages identified in our study, is possibly the most relevant ICF component to a patient’s experience of disability. This was demonstrated in previous studies (Saketkoo et al., 2014a; Saketkoo et al., 2014b) where patients with ILD almost exclusively discuss their condition in terms of activity and life participation aspects.

Considering real-world examples of an ICF Core Set or Checklist can help illustrate utility. An initial evaluation of a person with ILD in pulmonary rehabilitation, for example, elicits the top three concerns of living with ILD of which “coughing spells” is stated by the patient as the most pressing priority. The therapist advises that there are several strategies that can be taught and practiced in pulmonary rehabilitation to help manage and recover from coughing spells. The therapist might then work with the patient using the Core Set in ILD to identify the relevant categories that reflect life activities that they feel are most impaired by their experience of cough. Each of these patient-indicated categories can then be monitored over time via use of a numeric rating scale (NRS). The presentation of the Core Set helps support patient discussion in developing a personalized tool to gauge patient-perceived progress in areas that are of high priority for the patient. During the therapist’s query the patient expresses urinary incontinence during coughing spells has become a major issue. Though urinary incontinence may not be a part of the Core Set for ILD, it will be added to the patient’s list as a complication of cough that will be monitored over time.

The ICF linkage process, however, is limited in its transferability. For example in the case of PROM, ICF linkage demands that each question from a PROM be dissected into its single-concept units, with each linkage reflecting one concept of a question-item. Although inferences from an entire question-item can be made, the process does not accommodate joining of concept units to reflect the entirety of a question-item’s meaning.

ICF categories are dual-edged in that they are specific yet also generic. Each ICF category is sufficiently generic and able to be linked to many different health conditions (e.g. “ability to concentrate”, b140, may apply to diabetes, heart failure, traumatic brain injury, etc.), thus providing a comprehensive yet feasible system for tracking a type of disability. Whereas, the specific nature of the categories has potential to accurately capture the nature of symptomatic impairment. For example, b4402, “depth of inspiration” is a highly granular descriptor of a respiratory function (b440), and further still the following categories describing respiratory muscle function (b445) alone or in combination distinctively characterize respiratory muscle weakness: b4450, “thoracic” versus b4451, “diaphragmatic” versus b4452, “accessory” respiratory muscle function.

Some areas of ICF categories, can also be abstract, and devoid of contextual life circumstances. Such bare generic descriptions confer feasibility for clinical documentation purposes but pose limitations on accuracy and meaningfulness of patient query. In contrast, a single question from a PROM often contains several converging concepts reflective of a patient’s experience of that impairment, and thus an isolated ICF category may not hold strong patient-reported relevance a potential vulnerability in the ICD-11 implementation. The ICF is an evolving system that can tolerate expansion to include ICF categories that more closely reflect patient experiences of specific impairments and, thus, improve accuracy of patient responses.

Most included PROMs were developed with careful qualitative methods but have yielded significant conceptual variation. For example, the Dyspnea-12 (D-12) and L-IPF provide an ICF category, b4402, “depth of respiration”, which is a ubiquitous concern of patients with ILD (Saketkoo et al., 2014a; Saketkoo et al., 2014b) yet appears only in these two PROMs. This is also true of d7702, “sexual relationships”, which is meaningful to patients but only found in the USCD-SBQ. This lack of capture occurs in other health conditions, such as myositis, where intimacy and sexual relations are of high patient-reported importance in more private data-collection circumstances, such as surveys or semi-structured interviews. Patients may be more reticent to supply ultra-sensitive information in larger focus groups (Alexanderson et al., 2002; Alemo Munters et al., 2011).

In contrast, single-occurring linkages may also demonstrate weak relevance to the specific disease. In this study, d440, “fine hand use” from the SF-36, does not provide information relevant to ILD. However, the reason for continued use of a generic measure like the SF-36 lies in its global validation across diseases, making it an essential anchor and comparator.

The utility of an ICF Core Set in ILD also enables application to a CTD-ILD. Using the example of RA for which an ICF Core Set already exists, the current recommendation for RA-ILD would be to combine two separate ICF Core Sets, one for ILD and the RA (Stucki and Cieza, 2004). The development of ICF Core Sets in more multi-organ system predominant conditions like systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIMs) or sarcoidosis, are likely to incorporate an ILD ICF Core Set into their frameworks (Saketkoo et al., 2012b; Saketkoo et al., 2012c).

An important example highlighting the influence of analytic approach on patient-relevant concepts arose during K-BILD development. Academic curiosity spurred applications to the original dataset using Rasch analysis (resulting in the currently circulating K-BILD-R) and also item response theory resulting in K-BILD-I. Remarkably, only K-BILD-R retained the questions regarding financial solvency; while only K-BILD-I retained items on fatigue, a predominant concept in other ILD PROMs and both are crucial concepts for people living with ILD. This finding led to group discussion regarding “fatigue” persistently being relegated to a function of HRQoL in ILD. While it was agreed that there is value in re-examining “fatigue” in ILD as a complex and multi-dimensional core symptom domain (De Vries et al., 2000; De Vries et al., 2001; De Vries and Drent, 2006; Saketkoo et al., 2014a; Hendriks et al., 2018; Kølner-Augustson et al., 2020).

The ICF linkage provides an expansive view of the great wealth of these PROMs that may together be harmonized into a streamlined instrument incorporating the optimal aspects of each. Such an effort would entail wide global engagement of patients and patient partners in tightly iterative applications of consensus methodology and testing (Stucki and Cieza, 2004).

Recommendations for lung disease in the WHO ICF classification system

The ICF was designed to be broadly comprehensive rather than detail exhaustive. The ICF structure was intended to be responsive to modification and development over time, exemplified by the ICF evolution of “Personal Factors”. Our instrument linkage demonstrated essential symptoms related to chronic pulmonary and cardiovascular diseases that require consideration for inclusion in future ICF updates. Three of these essential areas are described below.

Biophysiologic mechanisms discussion

Cough is an intrinsic experience creating significant impairment in pulmonary disease. In ILD a restrictive physiology, inspiratory and predominantly dry cough creates significant interference in life activities. Phlegm production, though not as frequent or troubling in ILD as in COPD, is an essential descriptor of cough. Temporary placeholder categories were created through this investigation (e.g. b450_xx, b460_ xx or b469_xx) to capture the intrinsic in ILD and lung disease that currently lack sufficient representation in ICF language. Enduring additions to ICF were proposed to directly designate cough, inspiratory cough, dyspnea, wheeze, air hunger and phlegm production.

Psychosocial function discussion

Though not a direct bio-physical manifestation of pulmonary disease, patients perceive psychosocial impact as an intrinsic experience of ILD (De Vries et al., 2000; Swigris et al., 2005; Saketkoo et al., 2014a; Saketkoo et al., 2014b), especially when biophysical symptoms are present with rest or slight exertion, resulting in disabling breathlessness or cough and which appear to be deeply entwined with embarrassment, frustration, fear, safety with exertion, and loss of control. Capturing and describing the disease-related psychological impact of a non-psychiatric health condition is a current challenge within the ICF.

Several instruments contain question-items that measure degrees of frustration, disgust, embarrassment, distress, fear or sense of safety with exertion. Embarrassment, one such frequent descriptor, as an example, greatly impacts psychological functioning and coping with cough which is a ubiquitous experience drawing both visual and auditory unwanted attention in ILDs (De Vries et al., 2000; Swigris et al., 2005; Key et al., 2010; Jones et al., 2011; Theodore et al., 2012; Saketkoo et al., 2014a; Saketkoo et al., 2014b) and other lung conditions. These concepts are strongly echoed in ILD patient qualitative data (De Vries et al., 2000; Swigris et al., 2005; Saketkoo et al., 2014a; Saketkoo et al., 2014b) and perceived to influence level of functioning. These would be important dynamics for an ILD ICF Core Set but are yet awaiting evolution within ICF under the “personal factors” component.

Physical function discussion

The ICF’s generic nature can impede accurate symptom query and may warrant added contextualization of ICF descriptors. Activity-descriptors common in respiratory-related PROMs and patient-reported visit history that require significant cardiopulmonary exertion, such as mowing lawn and shoveling snow, are not sufficiently defined by current ICF categories. The closest combined categories for “mowing lawn” are d4551 “pushing” which is intended to describe upper extremity function buts lacks sufficient discrimination between cardiopulmonary, muscular or joint capability and d6505 “taking care of outdoor plants’. Elements of cardiopulmonary recovery (stopping, resting mid-activity), pace (e.g. performing more slowly; potentially related to recovery); punctuation of disease behavior (such as “attack”, “flaring”) as well as frequency of symptoms are temporal and dynamic associations essential to pulmonary disease requiring future ICF updates.

A proposal for future ICF revisions, is the addition of a discrete category or an additional component to the ICF that describes the global perception of disease burden from the patient’s perspective. The VAS-PtG is widely validated across many diseases as a reliable marker, sensitive to change and correlative with objective measures of disease activity (Singh et al., 2011; Bartlett et al., 2012). Its inclusion into the ICF could enhance report of perceived function and burden of disease as well as the incremental impact of modification of environmental factors.

Future steps

This study’s identification of 111 ICF categories, 34 “personal factors” and multiple further descriptors under “health condition” (hc) and “not defined” (nd) will develop into a manageable ICF Core Set over time (Kostanjsek et al., 2011; Finger et al., 2014). Our continuance of iterative multi-disciplinary methodological applications that include patient research partners as essential team members will refine and identify the most relevant and important concepts of both the somatic and psychosocial realms experienced by people living with ILD. Pursuant to this is working with the WHO ICF to address the expansion of descriptors to accurately reflect functional impairment intrinsic to living with ILD. Discussions amongst the authors presented creating central pathways to assess side effects of disease-related treatment beyond being under “environmental factors” but rather under “b” and “d” categories (Proesmans et al., 2019). Finally, the dedicated efforts in the development of past PROMs have provided a wealth of information that can result in a potentially streamlined exquisitely responsive instrument.

Conclusion

This is the first effort to examine ICF Core Sets in ILD. This investigation provided an important and useful step to facilitating clinician preparation for ICD-11 and other performance quality assessments that will require ICF use (Iezzoni and Greenberg, 2003; Health and Human Services/Centers for Medicare and Medicaid Services, 2000; SocialSecurity Administration, 2013; Escorpizo and Stucki, 2013). The utility of disease-specific ICF Core Sets is multi-factorial on individual, regional and global levels offering value to epidemiologic, health economics, clinical assessment, PROM development and comparison for fair representation in policy, service provision and research funding assessments as well as the potential development of concise PROMs. Future steps may build on harmonizing these PROMs to widely validate concepts, context and language in ILD. Our investigation identifies new ICF categories, for general pulmonary disease to be considered in the future ICF revisions.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Author contributions

Conception and design: LAS, RE, JV, KJK, KF, HA, HP, JP, MR, CV, SSB, DL, CS, MBS, MRL, OD, and AMR. Analysis and interpretation: LAS, RE, JV, KJK, KF, SSB, DL, CS, OKB, OD, LS, ERV, EB, TF, ONO, MD, KCP, and AMR. Manuscript drafting for important intellectual content: LAS, RE, JV, KJK, HAC, SSB, HA, HP, JP, MR, JL, LS, ER, JV, ML, MBS, OKB, OD, ERV, EJB, TF, CV, ONO, MD, KCP, and AMR.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.979788/full#supplementary-material

Abbreviations

CM, Center for Medicare and Medicaid Services, CTD, Connective Tissue Disease; DLCO, Diffusion Capacity of Lung for Carbon Monoxide; FVC, Forced Vital Capacity; HRCT, High Resolution Computed Tomography; ICD, International Classification of Diseases; ICF, International Classification of Functioning Disability and Health; IIP, Interstitial Idiopathic Pneumonitis; IPF, Idiopathic Pulmonary Fibrosis; PF/IPF-PROM, Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis Patient Reported Outcome Measure; ILD, Interstitial Lung Disease; K-BILD, King’s Brief Interstitial Lung Disease Questionnaire; L-IPF, Living with IPF; PSFS, Patient Specific Functional Scale; PROM, Patient-Reported Outcome Measures; PF, Pulmonary Fibrosis; pf, Personal factors; SF-36, Short Form 36; UCSD-SBQ, University of California-Shortness of Breath Questionnaire; WHO, World Health Organization.

References

Alemo Munters, L., Brodin, N., Löfberg, E., Stråt, S., and Alexanderson, H. (2014). Disabilities of importance for patients to improve--using a patient preference tool in rheumatoid arthritis. Disabil. Rehabil. 36 (21), 1762–1767. PMID: 24364534. doi:10.3109/09638288.2013.868535

CrossRef Full Text | Google Scholar

Alemo Munters, L., van Vollenhoven, R. F., and Alexanderson, H. (2011). Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis. ISRN Rheumatol. 2011, 463124. doi:10.5402/2011/463124

PubMed Abstract | CrossRef Full Text | Google Scholar

Alexanderson, H., Lundberg, I. E., and Stenström, C. H. (2002). Development of the myositis activities profile--validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J. Rheumatol. 29 (11), 2386–2392. PMID: 12415597.

PubMed Abstract | Google Scholar

Bartlett, S. J., Hewlett, S., Bingham, C. O., Woodworth, T. G., Alten, R., Pohl, C., et al. The OMERACT RA Flare Working Group (2012). Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined delphi consensus. Ann. Rheum. Dis. 71 (11), 1855–1860. doi:10.1136/annrheumdis-2011-201201

PubMed Abstract | CrossRef Full Text | Google Scholar

Cieza, A., Geyh, S., Chatterji, S., Kostanjsek, N., Ustun, B., and Stucki, G. (2005). ICF linking rules: An update based on lessons learned. J. Rehabil. Med. 37, 212–218. doi:10.1080/16501970510040263

PubMed Abstract | CrossRef Full Text | Google Scholar

Core Team, R. (2014). A language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing. URL http://www.R-project.org/.

Google Scholar

De Vries, J., and Drent, M. (2006). Quality of life and health status in interstitial lung diseases. Curr. Opin. Pulm. Med. 12 (5), 354–358. doi:10.1097/01.mcp.0000239553.93443.d8

PubMed Abstract | CrossRef Full Text | Google Scholar

De Vries, J., Kessels, B. L., and Drent, M. (2001). Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J. 17 (5), 954–961. doi:10.1183/09031936.01.17509540

PubMed Abstract | CrossRef Full Text | Google Scholar

De Vries, J., Seebregts, A., and Drent, M. (2000). Assessing health status and quality of life in idiopathic pulmonary fibrosis: Which measure should be used? Respir. Med. 94 (3), 273–278. doi:10.1053/rmed.1999.0736

PubMed Abstract | CrossRef Full Text | Google Scholar

Escorpizo, R., Kostanjsek, N., Kennedy, C., Nicol, M. M. R., Stucki, G., Ustun, T. B., et al. (2013). Harmonizing WHO's international classification of diseases (ICD) and international classification of functioning, disability and health (ICF): Importance and methods to link disease and functioning. BMC Public Health 13, 742. doi:10.1186/1471-2458-13-742

PubMed Abstract | CrossRef Full Text | Google Scholar

Escorpizo, R., and Stucki, G. (2013). Disability evaluation, social security, and the international classification of functioning, disability and health: The time is now. J. Occup. Environ. Med. 55 (6), 644–651. doi:10.1097/JOM.0b013e318297ae47

PubMed Abstract | CrossRef Full Text | Google Scholar

Fairbairn, K., May, K., Yang, Y., Balasundar, S., Hefford, C., Abbott, J. H., et al. (2012). Mapping patient-specific functional scale (PSFS) items to the international classification of functioning, disability and health (ICF). Phys. Ther. 92 (2), 310–317. PMID: 22074939. doi:10.2522/ptj.20090382

PubMed Abstract | CrossRef Full Text | Google Scholar

Finger, M. E., Selb, M., De Bie, R., and Escorpizo, R. (2014). Using the international classification of functioning, disability and health in physiotherapy in multidisciplinary vocational rehabilitation: A case study of low back pain. Physiother. Res. Int. 15, 231–241. doi:10.1002/pri.1587

CrossRef Full Text | Google Scholar

Health and Human Services/Centers for Medicare and Medicaid Services, NCVHS report 2000-2002 - Centers for Medicare and Medicaid services. Multi-year implementation of International Classification of Functioning, Disability and Health http://www.ncvhs.hhs.gov/wp-content/uploads/2014/05/00-02rpt.pdf (Accessed July 7, 2015).

Google Scholar

Hendriks, C., Drent, M., Elfferich, M., and De Vries, J. (2018). The fatigue assessment scale: Quality and availability in sarcoidosis and other diseases. Curr. Opin. Pulm. Med. 24 (5), 495–503. doi:10.1097/MCP.0000000000000496

PubMed Abstract | CrossRef Full Text | Google Scholar

Iezzoni, L. I., and Greenberg, M. S. (2003). Capturing and classifying functional status information in administrative databases. Health Care Financ. Rev. 24 (3), 61–76.

PubMed Abstract | Google Scholar

Jones, R. M., Hilldrup, S., Hope-Gill, B. D., Eccles, R., and Harrison, N. K. (2011). Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough 107, 2. doi:10.1186/1745-9974-7-2

PubMed Abstract | CrossRef Full Text | Google Scholar

Key, A. L., Holt, K., Hamilton, A., Smith, J. A., and Earis, J. E. (2010). Objective cough frequency in idiopathic pulmonary fibrosis. Cough 6, 4. doi:10.1186/1745-9974-6-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Kohler, F., Selb, M., Escorpizo, R., Kostanjsek, N., Stucki, G., Riberto, M., et al. (2012). Towards the joint use of ICD and ICF: A call for contribution. J. Rehabil. Med. 44 (10), 805–810. doi:10.2340/16501977-1062

PubMed Abstract | CrossRef Full Text | Google Scholar

Kølner-Augustson, L., Prior, T. S., Skivild, V., Aalestrup, A., and Bendstrup, E. (2020). Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment. Eur. Clin. Respir. J. 8 (1), 1853658. doi:10.1080/20018525.2020.1853658

PubMed Abstract | CrossRef Full Text | Google Scholar

Kostanjsek, N., Escorpizo, R., Boonen, A., Walsh, N. E., Ustun, T. B., and Stucki, G. (2011). Assessing the impact of musculoskeletal health conditions using the international classification of functioning, disability and health. Disabil. Rehabil. 33 (13-14), 1281–1297. doi:10.3109/09638288.2010.526165

PubMed Abstract | CrossRef Full Text | Google Scholar

Patel, A. S., Siegert, R. J., Brignall, K., Gordon, P., Steer, S., Desai, S. R., et al. (2012). The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 67 (9), 804–810. doi:10.1136/thoraxjnl-2012-201581

PubMed Abstract | CrossRef Full Text | Google Scholar

Patient specific functional scale. London, United Kingdom: Physiopedia. https://www.physio-pedia.com/Patient_Specific_Functional_Scale. [Accessed 18 March 2021].

PubMed Abstract | Google Scholar

Proesmans, V. L. J., Drent, M., Elfferich, M. D. P., Wijnen, P. A. H. M., Jessurun, N. T., and Bast, A. (2019). Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung 197 (5), 551–558. doi:10.1007/s00408-019-00260-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Ruaro, B., Baratella, E., Confalonieri, P., Wade, B., Marrocchio, C., Geri, P., et al. (2021). High-resolution computed Tomography: Lights and shadows in improving care for SSc-ILD patients. Diagn. (Basel) 11 (11), 1960. doi:10.3390/diagnostics11111960

CrossRef Full Text | Google Scholar

Russell, A-M., Jones, G., Saketkoo, L., Doyle, A-M., Sanderson, T., D'Accord, C., et al. (2017). Development and preliminary testing of the idiopathic pulmonary fibrosis patient reported outcome measure (IPF-PRoM): UK and Ireland multi-centre study. American Thoracic Society International Conference: American Thoracic Society, A1031.

Google Scholar

Russell, A-M. (2018). Development and testing of an idiopathic pulmonary fibrosis (IPF) patient reported outcome measure (PROM). Doctoral thesis. London, United Kingdom: Imperial College London. doi:10.25560/86249

CrossRef Full Text | Google Scholar

Saketkoo, L. A., Escorpizo, R., Keen, K. J., Fligelstone, K., and Distler, O. (2012). International classification of functioning, disability and health core set construction in systemic sclerosis and other rheumatic diseases: A EUSTAR initiative. Rheumatol. Oxf. 51 (12), 2170–2176. doi:10.1093/rheumatology/kes185

PubMed Abstract | CrossRef Full Text | Google Scholar

Saketkoo, L. A., Escorpizo, R., Keen, K. J., Fligelstone, K., and Distler, O. Results from a multi-tiered item collection on linking systemic sclerosis to the international classification of functioning, disability and health: A eular scleroderma trials and research initiative. 2012 ACR/ARHP annual meeting. Abstract 717. Full details: https://acrabstracts.org/abstract/results-from-a-multi-tiered-item-collection-on-linking-systemic-sclerosis-to-the-international-classification-of-functioning-disability-and-health-a-eular-scleroderma-trials-and-research-initiative/.

Google Scholar

Saketkoo, L. A., Escorpizo, R., Keen, K. J., Fligelstone, K., and Distler, O. (2012). International classification of functioning, disability and health core set construction in systemic sclerosis and other rheumatic diseases: A EUSTAR initiative. Rheumatol. Oxf. 51 (12), 2170–2176. doi:10.1093/rheumatology/kes185

PubMed Abstract | CrossRef Full Text | Google Scholar

Saketkoo, L. A., Mittoo, S., Frankel, S., LeSage, D., Sarver, C., Phillips, K., et al. (2014a). Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. J. Rheumatol. 41 (4), 792–798. doi:10.3899/jrheum.131251

PubMed Abstract | CrossRef Full Text | Google Scholar

Saketkoo, L. A., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P. F., Distler, O., et al. (2014b). Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: Provisional core sets of domains and instruments for use in clinical trials. Thorax 69 (5), 428–436. doi:10.1136/thoraxjnl-2013-204202

PubMed Abstract | CrossRef Full Text | Google Scholar

Selb, M., Escorpizo, R., Kostanjsek, N., Stucki, G., Ustun, B., and CiezA, A. (2015). A guide on how to develop an international classification of functioning, disability and health core set. Eur. J. Phys. Rehabil. Med. 51 (1), 105–117.

PubMed Abstract | Google Scholar

Selb, M., Kohler, F., Robinson Nicol, M. M., Riberto, M., Stucki, G., Kennedy, C., et al. (2015). ICD-11: A comprehensive picture of health, an update on the ICD-ICF joint use initiative. J. Rehabil. Med. 47 (1), 2–8. doi:10.2340/16501977-1928

PubMed Abstract | CrossRef Full Text | Google Scholar

Singh, J. A., Yang, S., Strand, V., Simon, L., Forsythe, A., Hamburger, S., et al. (2011). Validation of pain and patient global scales in chronic gout: Data from two randomised controlled trials. Ann. Rheum. Dis. 70 (7), 1277–1281. doi:10.1136/ard.2010.144022

PubMed Abstract | CrossRef Full Text | Google Scholar

Social Security Administration, (2013). Notice of solicitation of public and federal agency comments for collaboration on evaluating the World Health Organization (WHO) International Classification of Functioning, Disability andHealth (ICF) standard for coding functional capability in federal programs. Available at http://www.gpo.gov/fdsys/pkg/FR-2013-01-02/pdf/2012-31479.pdf (Accessed July 7, 2015).

Google Scholar

Spagnolo, P., Tzouvelekis, A., and Bonella, F. (2018). The management of patients with idiopathic pulmonary fibrosis. Front. Med. 5, 148. doi:10.3389/fmed.2018.00148

CrossRef Full Text | Google Scholar

Stamm, T. A., Cieza, A., Machold, K. P., Smolen, J. S., and Stucki, G. (2004). Content comparison of occupation-based instruments in adult rheumatology and musculoskeletal rehabilitation based on the international classification of functioning, disability and health. Arthritis Rheum. 51 (6), 917–924. doi:10.1002/art.20842

PubMed Abstract | CrossRef Full Text | Google Scholar

Stratford, P., Gill, C., Westaway, M., and Binkley, J. (1995). Assessing disability and change on individual patients: A report of a patient specific measure. Physiother. Can. 47 (4), 258–263. doi:10.3138/ptc.47.4.258

CrossRef Full Text | Google Scholar

Stucki, G., and Cieza, A. (2004). The international classification of functioning, disability and health (ICF) core sets for rheumatoid arthritis: A way to specify functioning. Ann. Rheum. Dis. 63 (II), ii40–ii45. ii40–ii45. doi:10.1136/ard.2004.028233

PubMed Abstract | CrossRef Full Text | Google Scholar

Swigris, J. J., Andrae, D. A., Churney, T., Johnson, N., Scholand, M. B., White, E. S., et al. (2020). Development and initial validation analyses of the living with idiopathic pulmonary fibrosis questionnaire. Am. J. Respir. Crit. Care Med. 202 (12), 1689–1697. doi:10.1164/rccm.202002-0415OC

PubMed Abstract | CrossRef Full Text | Google Scholar

Swigris, J. J., Stewart, A. L., Gould, M. K., and Wilson, S. R. (2005). Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual. Life Outcomes 3, 61. doi:10.1186/1477-7525-3-61

PubMed Abstract | CrossRef Full Text | Google Scholar

Theodore, A. C., Tseng, C. H., Li, N., Elashoff, R. M., and Tashkin, D. P. (2012). Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: Findings from the scleroderma lung study. Chest 142 (3), 614–621. doi:10.1378/chest.11-0801

PubMed Abstract | CrossRef Full Text | Google Scholar

Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., et al. (2013). An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188 (6), 733–748. doi:10.1164/rccm.201308-1483ST

PubMed Abstract | CrossRef Full Text | Google Scholar

Wijsenbeek, M., and Cottin, V. (2020). Spectrum of fibrotic lung diseases. N. Engl. J. Med. 383 (10), 958–968. doi:10.1056/NEJMra2005230

PubMed Abstract | CrossRef Full Text | Google Scholar

World Health Organization International Classification of Functioning Disability and Health (2001). Complete English classification. Geneva: World Health Organization. Available at: http://psychiatr.ru/download/1313?view=1&name=ICF_18.pdf (Accessed July 1, 2015).

Google Scholar

World Health Organization (2001). International classification of functioning, disability and health: ICF. Geneva: World Health Organization Website. Available at: http://www.who.int/classifications/icf/appareas/en/index.html (Accessed July 1, 2015).

Google Scholar

World Health Organization Website, . http://www.who.int/classifications/icf/appareas/en/index.html (Accessed July 1, 2015).

Keywords: fibrosis, ICD-11, patient-reported outcomes, connective tissue, cough, CTD-ILD

Citation: Saketkoo LA, Escorpizo R, Varga J, Keen KJ, Fligelstone K, Birring SS, Alexanderson H, Pettersson H, Chaudhry HA, Poole JL, Regardt M, LeSage D, Sarver C, Lanario J, Renzoni E, Scholand MB, Lammi MR, Kowal-Bielecka O, Distler O, Frech T, Shapiro L, Varju C, Volkmann ER, Bernstein EJ, Drent M, Obi ON, Patterson KC, Russell A-M and The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS) (2022) World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease. Front. Pharmacol. 13:979788. doi: 10.3389/fphar.2022.979788

Received: 27 June 2022; Accepted: 13 July 2022;
Published: 14 October 2022.

Edited by:

Barbara Ruaro, University of Trieste, Italy

Reviewed by:

Alessia Giovanna Andrisano, Azienda Ospedaliero Universitaria Ospedali Riuniti Di Trieste, Italy
Stefano Tavano, University of Trieste, Italy

Copyright © 2022 Saketkoo, Escorpizo, Varga, Keen, Fligelstone, Birring, Alexanderson, Pettersson, Chaudhry, Poole, Regardt, LeSage, Sarver, Lanario, Renzoni, Scholand, Lammi, Kowal-Bielecka, Distler, Frech, Shapiro, Varju, Volkmann, Bernstein, Drent, Obi, Patterson, Russell and The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lesley Ann Saketkoo, lsaketk@tulane.edu; Anne-Marie Russell, a.russell4@exeter.ac.uk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.